About
Continuing Education
Program
Register
Sponsorship
Next Gen Banner

Virtual Next Generation Migraine Therapies 

Jan12021

The Next Generation Migraine Therapies (NGMT) initiative is a comprehensive program designed to provide a multi-faceted approach to migraine education offered at no cost to healthcare providers. Brought to you by the American Headache Society, the program covers diagnosis and treatment of migraine and updates on the latest science.

In December 2020, the NGMT program will launch virtually on the AHS Education On Demand platform! The virtual program will center around pre-recorded lectures on new acute migraine treatments and new migraine prevention; behavioral approaches in migraine; and migraine diagnosis, epidemiology, and pathophysiology.

Live Q&A

NGMT registrants will also have access to live Q&A sessions with migraine experts for additional CME. Please visit the Education On Demand platform once registered to sign up for an upcoming Q&A.

Register Today

Next Gen Banner

Virtual Next Generation Migraine Therapies 

Jan12021

Who Should Attend

This program is designed for neurologists, family practitioners, internists and other health professionals who would like more information on the proper diagnosis and treatment of chronic migraine patients.

Accreditation Statement
The American Headache Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement 

The American Headache Society® designates this enduring material for a maximum of 2.75 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

COMMERCIAL SUPPORT DISCLOSURE

AHS gratefully acknowledges the educational support of the Next Generation Migraine Therapies Program from our industry supporters:

Allergan, an AbbVie company (NYSE: ABBV)
Eli Lilly and Company

Next Gen Banner

Virtual Next Generation Migraine Therapies 

Jan12021

Next Generation Migraine Therapies will launch virtually via the AHS Education On Demand platform.

Pre-recorded Lectures Available On Demand
Introduction and Program Overview
Kathleen B. Digre, MD, FAHS
Migraine Diagnosis, Epidemiology, and Pathophysiology
Kathleen B. Digre, MD, FAHS
What’s New in Acute Migraine Treatment
Stewart J. Tepper, MD, FAHS
Behavioral Approaches in Migraine Management
Dawn C. Buse, PhD, FAHS
What’s New in Migraine Prevention
Michael Marmura, MD, FAHS

Live Q&A*

*Separate registration required. Please register for the virtual program here, watch the on demand content, and then register separately for a live Q&A date that works for you via the Education On Demand platform.

Monday, December 14, 2020

5:00pm PST/8:00pm EST
Moderator: Richard B. Lipton, MD, FAHS

Presenters:
Scott W. Powers, PhD, FAHS
Rashmi B. Halker Singh, MD, FAHS
Franchesca Fiorito, MD

Saturday, February 20, 2021

9:00am PST/12:00pm EST
Moderator:  Peter J. Goadsby, MD, PhD, FAHS

Presenters:
Scott W. Powers, PhD, FAHS
Anna Pace, MD
Andrew D. Hershey, MD, PhD, FAHS

Wednesday, March 24, 2021

5:00pm PDT/8:00pm EDT
Moderator:  Kathleen B. Digre, MD, FAHS

Presenters:
Steven M. Baskin, PhD
Anna Pace, MD
Jennifer McVige, MD
Chaouki K. Khoury, MD, MS, FAHS

Next Gen Banner

Virtual Next Generation Migraine Therapies 

Jan12021

Online registration is now open. To register at no cost, click here.

Once registered, please visit the Education On Demand platform to watch pre-recorded sessions and sign up for an upcoming Q&A*.

*Please note the registration system is not linked to the Education On Demand platform and may take up to a week for your registration to be added. If you are unable to access the meeting after that time, please email us at ahshq@talley.com or call 856-423-0043.

Next Gen Banner

Virtual Next Generation Migraine Therapies 

Jan12021

AHS gratefully acknowledges the educational support of the Next Generation Migraine Therapies Program from our industry supporters:

Allergan, an AbbVie company (NYSE: ABBV)
Eli Lilly and Company